Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but there is a paucity of data identifying its therapeutic efficacy. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated using a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus neutralization assay with Vero-E6-TMPRSS2 cells; a commercial IgG and IgA ELISA to detect the spike (S) protein S1 domain (EUROIMMUN); IgA, IgG, and IgM indirect ELISAs to detect the full-length S protein or S receptor-binding domain (S-RBD); and an IgG avidity assay. We used multiple linear regression and predictive models to assess the correlations between antibody responses and demographic and…

• UD
  U.S. Department of Defense

  Award: W911QY2090012
• DO
  Division of Intramural Research, National Institute of Allergy and Infectious Diseases
• IS
  Icahn School of Medicine at Mount Sinai
• BP
  Bloomberg Philanthropies
• NI
  National Institutes of Health

  Awards: AI15207, AI052733, R01HL059842, R01AI120938, HHSN272201400007C, R01AI120938S1, USA-WA1/2020, NR-5228, R01AI128779, U54AG062333, T32A1007417
• CF
  Centers for Disease Control and Prevention
• NH
  National Heart, Lung, and Blood Institute

  Awards: AI052733, 1K23HL151826, R01HL059842
• NI
  National Institute of Allergy and Infectious Diseases

  Awards: T32A1007417, HHSN272201400007C, AI052733, R01AI128779, AI15207, R01AI120938
• ND
  NHLBI Division of Intramural Research

  Award: 1K23HL151826